

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A25	4,497,796	02/05/85	Salser <i>et al.</i>	514	44	12/08/82
	A26	4,675,382	06/23/87	Murphy	260	112	11/06/85
	A27	4,740,461	10/15/96	Kufe <i>et al.</i>	435	69.1	12/24/83
	A28	4,894,227	01/16/90	Stevens <i>et al.</i>	424	085.200	05/29/87
	A29	4,963,484	10/16/90	Kufe	435	069.300	01/29/88
	A30	5,053,489	10/01/91	Kufe	530	350	01/27/89
	A31	5,080,898	01/14/92	Murphy	424	94.1	02/21/89
	A32	5,380,712	01/10/95	Ballance <i>et al.</i>	514	12	02/14/92
	A33	5,565,334	10/17/94	Kufe <i>et al.</i>	435	69.1	10/17/94
	A34	5,965,386	10/12/99	Kerry-Williams <i>et al.</i>	435	69.1	03/01/95
	A35	6,004,746	12/21/99	Brent <i>et al.</i>	435	6	07/20/95
	A36	6,716,966	04/06/04	Madiyalakan <i>et al.</i>	530	387.1	08/18/00
	A37	6,344,203	02/05/02	Sandrin	424	277.1	06/23/98
	A38	7,147,850	12/12/06	Madiyalakan	514	12	11/26/01

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B17	WO 91/09867	07/11/99	WIPO	English
	B18	WO 99/23114	05/14/99	WIPO	English

65096958.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C223	"MUC-1/X mucin short variant," GenBank Accession No.: AAD10856, dated June 5, 2001.
	C224	"MUC-1/Z mucin short variant," GenBank Accession No.: AAD10858, dated June 5, 2001.
	C225	"Mucin 1 precursor, non-repetitive splice from Y [validated] – human," GenBank Accession No.: S48146, dated April 20, 2000.
	C226	Abe <i>et al.</i> , "Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene," <i>Proc. Natl. Acad. Sci. USA.</i> , 90:282-286, 1993.
	C227	Abe <i>et al.</i> , "Identification of a family of high molecular weight tumor-associated glycoproteins," <i>J. Immun.</i> , 139:257-261, 1987.
	C228	Abe <i>et al.</i> , "Sequence Analysis of the 5' region of the human DF3 breast carcinoma-associated antigen gene," <i>Bio. Biophys. Research Comm.</i> , 165:644-649, 1989.
	C229	Abe <i>et al.</i> , "Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells," <i>Cancer Res.</i> , 44:4574-4577, 1984.
	C230	Abe <i>et al.</i> , "Structural analysis of the DF3 human breast carcinoma-associated protein," <i>Cancer Res.</i> , 49:2834-2839, 1989.
	C231	Abe <i>et al.</i> , "Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells," <i>J. Cell. Physio.</i> , 143:226-231, 1990.
	C232	Apostolopoulos <i>et al.</i> , "Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein," <i>British J. Cancer.</i> , 67:713-720, 1993.
	C233	Arkle <i>et al.</i> , "Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers," <i>Int. J. Cancer</i> , 28:23-29, 1981.
	C234	Barrett <i>et al.</i> , "PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?," <i>Int. J. Cancer</i> , 101:581-588, 2002.
	C235	Bass, "The short answer," <i>Nature</i> , 411:428-429, 2001.
	C236	Burchell <i>et al.</i> , "A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes," <i>Int. J. Cancer</i> , 44:691-696, 1989.

65096958.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's		Applicant: Donald W. KUFE Surender KHARBANDA	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C237	Burchell <i>et al.</i> , "Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin," <i>Cancer Res.</i> , 47:5476-5482, 1987.
	C238	Burton <i>et al.</i> , "Epithelial mucin (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma," <i>Clin. Can. Res.</i> , 5:3065s-3072s, 1999.
	C239	Cawley <i>et al.</i> , "Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-Diphtheria fragment A is nontoxic," <i>Cell</i> , 22:563-570, 1980.
	C240	Chang <i>et al.</i> , "Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate," <i>J. Biol. Chem.</i> , 252:1515-1522, 1977.
	C241	Chaudhary <i>et al.</i> , "Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin," <i>Proc. Natl. Acad. Sci. USA</i> , 84:4538-4542, 1987.
	C242	Croghan <i>et al.</i> , "Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22," <i>Cancer Res.</i> , 43:4980-4988, 1983.
	C243	Cunningham <i>et al.</i> , "Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats," <i>Exp. Neurol.</i> , 163:457-468, 2000.
	C244	Cunningham <i>et al.</i> , "Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin," <i>J. Neurosci.</i> , 18:7047-7060, 1998.
	C245	Cunningham <i>et al.</i> , "Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells," <i>Exp. Neurol.</i> , 177:32-39, 2002.
	C246	Elbashir <i>et al.</i> , "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>EMBO Journal</i> , 20:6877-6888, 2001.
	C247	Fontenot <i>et al.</i> , "Biophysical characterization of one-, two-, and three-tandem repeats of human musin (muc-1) protein core," <i>Cancer Research</i> , 53:5386-5394, 1993.
	C248	Gay <i>et al.</i> , "Selective BRB2 SH2 inhibitors as anti-RAS therapy," <i>Int. J. Cancer</i> , 83:235-241, 1999.
	C249	George, D.G. et al., "Chapter 12. Current Methods in Sequence Comparison and Analysis," in: <i>Macromolecular Sequencing and Synthesis. Selected Methods and Applications</i> , Alan R. Liss, Inc., pp. 127-149, 1988.

65096958.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C250	Gutierrez <i>et al.</i> , "Gene therapy for cancer," <i>The Lancet</i> , 339:715-721, 1992.
	C251	Harlow and Lane, "Antibodies, A Lab Manual," Cold Spring Harbor, 1988.
	C252	Harris <i>et al.</i> , "Therapeutic antibodies – the coming of age," <i>Tibtech</i> , 11:12-44, 1993.
	C253	Hayes <i>et al.</i> , "Comparison of circulating CA15-3 and carcineembryonic antigen levels in patients with breast cancer," <i>J. Clin. Oncol.</i> , 4:1542-1550, 1986.
	C254	Hayes <i>et al.</i> , "Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen," <i>Blood</i> , 71:436-440, 1988.
	C255	Hilkens <i>et al.</i> , "Biosynthesis of MAM-6, an epithelial sialomucin," <i>J. Biol. Chem.</i> , 263:4215-4222, 1988.
	C256	Hilkens <i>et al.</i> , "Complexity of MAM-6, an epithelial sialomucin associated with carcinomas," <i>Cancer Res.</i> , 49:786-793, 1989.
	C257	Hilkens <i>et al.</i> , "Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors," <i>Int. J. Cancer</i> , 34:197-206, 1984.
	C258	Hopp, "Protein surface analysis. Methods for identifying antigenic determinants and other interaction sites," <i>J. Immunol. Methods</i> , 88:1-18, 1986.
	C259	Houghton <i>et al.</i> , "Monoclonal antibodies: potential applications to the treatment of cancer," <i>Seminars in Oncology</i> , 13:165-179, 1986.
	C260	Hug <i>et al.</i> , "Liposomes for the transformation of eukaryotic cells," <i>Biochem. Biophys. Acta.</i> , 1097:1-17, 1991.
	C261	Hull <i>et al.</i> , "Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinomas cell line," <i>Cancer Commun.</i> , 1:261-267, 1989.
	C262	Julian and Carson, "Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 293:1183-1190, 2002.
	C263	Kam <i>et al.</i> , "MUC1 synthetic peptide inhibition of intracellular adhesion molecule-1 and MUC1 binding requires six tandem repeats," <i>Cancer Res.</i> , 58:5577-5581, 1988.
	C264	Karlsson <i>et al.</i> , "A genetic polymorphism of a human urinary mucin," <i>Ann. Hum. Genet.</i> , 47:263, 1983.

65096958.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's		Applicant: Donald W. KUFE Surender KHARBANDA	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C265	Kotera <i>et al.</i> , "Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in Ser from breast, pancreatic, and colon cancer patients," <i>Cancer Research</i> , 54:2856-2860, 1994.
	C266	Lancaster <i>et al.</i> , "Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit," <i>Biochm. Biophys. Res. Comm.</i> , 173:1019-1029, 1990.
	C267	Lundy <i>et al.</i> , "Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients," <i>Breast Cancer Res. Treat.</i> , 5:269-276, 1985.
	C268	Manome <i>et al.</i> , "Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir," <i>Cancer Research</i> , 54:5408-5413, 1994.
	C269	McGrath <i>et al.</i> , "The Yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-Glycoprotein," <i>Nature</i> , 340:400, 1989.
	C270	Melani <i>et al.</i> , "Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb," <i>Cancer Research</i> , 51:2897-2901, 1991.
	C271	Neyfakh <i>et al.</i> , "Efflux-mediated multidrug resistance in bacillus subtilis: similarities and dissimilarities with the mammalian system," <i>Proc. Natl. Acad. Sci. USA</i> , 88:4781-4785, 1991.
	C272	Oosterkamp <i>et al.</i> , "Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z)," <i>Int. J. Cancer</i> , 72:87-94, 1997.
	C273	Orkin <i>et al.</i> , "Report & Recommendations of The Panel to Assess the NIH Investment in Research on Gene Therapy," 1995.
	C274	Pandy <i>et al.</i> , "Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein," <i>Cancer Res.</i> , 55:4000-4003, 1995.
	C275	Parry <i>et al.</i> , "Identification of MUC1 proteolytic cleavage sites in vivo," <i>Biochem. Biophys. Res. Commun.</i> , 283:715-720, 2001.
	C276	Porter <i>et al.</i> , "A neural survival factor is a candidate oncogene in breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> , 100:10931-10936, 2003.
	C277	Price <i>et al.</i> , "Immunological and structural features of the protein core of human polymorphic epithelial mucin," <i>Molecular Immunology</i> , 27:795-802, 1990.

65096958.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C278	Rewcastle <i>et al.</i> , "Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-Bromophenyl) amino]-6-(methylamino)-pyridine [3,4-d] pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors," <i>J. Med. Chem.</i> , 41:742-751, 1998.
	C279	Schroeder <i>et al.</i> , "Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland," <i>J Biol Chem</i> , 276:13057-13064, 2001.
	C280	Sekine <i>et al.</i> , "Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas," <i>J. Immunol.</i> , 135:3610-3615, 1985.
	C281	Sherman <i>et al.</i> , "Ionizing radiation regulates expression of the c-jun protooncogene," <i>Proc. Natl. Acad. Sci. USA</i> , 87:5663-5666, 1990.
	C282	Sloan <i>et al.</i> , "Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology," <i>Cancer</i> , 47:1786-1795, 1981.
	C283	Struhl, "Deletion mapping a eukaryotic promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 78:4461-4465, 1981.
	C284	Swallow <i>et al.</i> , "The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM," <i>Nature</i> , 328:82-84, 1987.
	C285	Tondini <i>et al.</i> , "Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer," <i>Cancer Res.</i> , 48:4107-4112, 1988.
	C286	Vleck <i>et al.</i> , "Pseudorabies virus immediate-early gene overlaps with an oppositely oriented open reading frame: Characterization of their promoter and enhancer regions," <i>Virology</i> , 179:365,337, 1990.
	C287	Van Zonneveld <i>et al.</i> , "Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5525-5529, 1988.
	C288	Waldmann, "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> 252:1657-1662, 1991.
	C289	Xing <i>et al.</i> , "Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies," <i>Cancer Research</i> , 50:89-96, 1990.
	C290	Xing <i>et al.</i> , "Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions," <i>Immunology</i> , 72:304-311, 1991.

65096958.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
<b>List of Patents and Publications for Applicant's</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <small>(Use several sheets if necessary)</small>		<b>Applicant:</b> <b>Donald W. KUFE</b> <b>Surender KHARBANDA</b>	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-7</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C291	Xing <i>et al.</i> , "Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies," <i>Molecular Immunology</i> , 29:641-650, 1992.
	C292	Xing <i>et al.</i> , "Monoclonal antibodies reactive with mucin expressed in breast cancer," <i>Immunol. Cell. Biol.</i> , 67:183-195, 1989.
	C293	Xing <i>et al.</i> , "Second generation anti-MUC1 peptide monoclonal antibodies, <i>Cancer Research</i> , 52:2310-2317, 1992.
	C294	Yeh <i>et al.</i> , "Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate," <i>Proc. Natl. Acad. Sci. USA</i> , 89:1904-1908, 1992.

65096958.1

EXAMINER:	/Sean McGarry/	DATE CONSIDERED:	/Sean McGarry/
-----------	----------------	------------------	----------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/**